Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 1 Issue 9, September 2020

Volume 1 Issue 9

Oncolytic nanoparticle immunotherapeutics

Self-replicating lipid nanoparticles encoding IL-12 RNA induce priming of CD8+ T cells and immunogenic cell death in established tumors.

See Li et al. and the News & Views article by Kepp and Kroemer.

Image: Yingzhong Li, The David Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. Cover Design: Lauren Heslop.


  • Editorial |

    The need to address COVID-19 is placing huge demands on biomedical research and regulatory processes. Under pressure, it is essential to uphold high bioethical principles and rigorous standards for the development and approval of medicines.

News & Views

  • News & Views |

    Immunotherapy has changed the treatment paradigm for patients with cancer, but patient selection, response assessment and treatment duration require further refinement. A recent study reports that the kinetics of circulating tumor DNA reflect response and resistance to immunotherapy treatment across multiple cancer types and could be used to tailor treatment.

    • Jeanne Tie
  • News & Views |

    Locally injected lipid nanoparticles that deliver RNA to elicit danger signals and simultaneously contain RNA that encodes a membrane-anchored version of the cytokine IL-12 can induce immunogenic cell death in tumors. This multipronged platform induces anticancer immune responses to the injected lesion as well as to distant tumors and hence produces an abscopal effect.

    • Oliver Kepp
    • Guido Kroemer
  • News & Views |

    The urea cycle enzyme argininosuccinate synthase 1 (ASS1) is upregulated in some cancer types. A study now shows that tumor cells with elevated urea cycle activity due to high ASS1 expression enhance gluconeogenesis, enabling a metabolic shift toward serine synthesis and causing purine synthesis addiction for growth and proliferation.

    • Elodie Villa
    • Issam Ben-Sahra


  • Review Article |

    Zhang and Meyerson review exciting advances in methodologies, models and datasets to study noncoding alterations in cancer, new insights into their roles in disease and potential translational implications.

    • Xiaoyang Zhang
    • Matthew Meyerson


Amendments & Corrections


Quick links